Jody Fink
Optometrist · Belgrade, MTNPI 1730278268
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $561 of the $641 with a category attached, or 87.5%. Alcon accounts for 61.6% of it on its own, with 7 other manufacturers making up the rest.
Across 19 payments — averaging $33.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$395
- Coopervision Inc.$76
- Optos, Inc.$63
- AbbVie$32
- Bausch & Lomb Americas Inc.$24
- Aerie Pharmaceuticals, Inc.$19
- plus $33 from 2 others
What the payments were for
- Food & beverage$56187%
- Gifts$173%
- Entertainment$6310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 11 | $395 |
| Coopervision Inc. | 2 | $76 |
| Optos, Inc. | 1 | $63 |
| AbbVie | 1 | $32 |
| Bausch & Lomb Americas Inc. | 1 | $24 |
| Aerie Pharmaceuticals, Inc. | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Biotissue Holdings Inc. | 1 | $16 |
How this compares
$641 in reported general payments places this provider in the 70th percentile of 184 optometrist providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 22 | $22,262 |
| LumiganBimatoprost | 20 | $7,985 |
| Fluorometholone | 13 | $896 |
| Latanoprost | 65 | $381 |
| ErythromycinErythromycin Base | 22 | $262 |
| Azithromycin | 11 | $192 |
| Timolol Maleate | 14 | $128 |
| Brimonidine Tartrate | 12 | $74 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $32 | $30,24842 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 184 optometrist providers in Montana.
Other optometrist in Belgrade
- Douglas KimballBelgrade$1K
- David BauerBillings$4K
- Marisa HessLivingston$4K
- Dirk BeyerHamilton$4K
- Joseph VincentGreat Falls$3K
- Justine RedlinGreat Falls$3K
- Christopher QuallsHamilton$2K
- Travis WhittBozeman$2K
- Mariah MitmanHamilton$2K
- Jennipher HarperBozeman$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.